Spectrum Pharmaceuticals, Inc. - SPPI STOCK NEWS

Spectrum Pharmaceuticals (NASDAQ: SPPI) will participate in the JMP Securities Hematology and Oncology Summit on December 7, 2021, at 2:40 p.m. ET. A live webcast of the event will be available on the company's website, with a replay to follow shortly after.

Spectrum is focused on novel oncology therapies and has a late-stage pipeline aimed at addressing unmet medical needs. Their strategic focus includes acquiring and developing innovative drugs while ensuring regulatory compliance and competitive market presence.

Spectrum Pharmaceuticals (NASDAQ: SPPI) will participate in the 2021 Jefferies London Healthcare Conference, featuring a virtual fireside chat available on-demand from November 18, 2021, at 3 a.m. ET/8 a.m. GMT. Attendees can access the webcast via the Investor Relations section of the company’s website. Spectrum is focused on developing novel oncology therapies and has a robust pipeline aimed at addressing unmet medical needs in cancer care. This participation underscores the company's commitment to engaging with investors and showcasing its growth potential.

Spectrum Pharmaceuticals (NasdaqGS: SPPI) reported a net loss of $33.1 million or $0.21 per share for Q3 2021, an improvement from a loss of $48.5 million in Q3 2020. Poziotinib's NDA submission is on track for 2021 under Fast Track designation, with promising ESMO Congress data showing a 44% objective response rate in patients with HER2 mutations. ROLONTIS' manufacturing issues are expected to be resolved by year-end following a productive FDA meeting. The company ended Q3 with $133.6 million in cash and securities, indicating a solid financial position for future developments.

Spectrum Pharmaceuticals (SPPI) announced a conference call on November 10, 2021, at 4:30 p.m. Eastern to discuss its Q3 2021 financial results and provide a corporate update. The call will be accessible via phone and streamed on their Investor Relations website. Spectrum is focused on developing targeted oncology therapies and has a pipeline aimed at addressing unmet medical needs, indicating potential future growth.

Spectrum Pharmaceuticals (SPPI) announced preclinical data showcasing the synergistic effects of poziotinib combined with KRAS inhibitors on KRAS^G12C mutant cancer cell lines. The findings, presented by Dr. Jacqulyne Robichaux at the Virtual International Conference on Molecular Targets and Cancer Therapeutics, emphasize the importance of pan-ErbB inhibition in enhancing KRAS^G12C inhibitor efficacy. Chief Medical Officer Francois Lebel expressed optimism about the potential clinical implications for patients with non-small cell lung cancer (NSCLC) and other solid tumors with KRAS mutations.

Spectrum Pharmaceuticals (NASDAQ: SPPI) will participate in the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021, at 1:20 p.m. ET. A live webcast of the fireside chat will be available on the Investor Relations section of their website, with a replay offered shortly after the event. Spectrum focuses on developing novel and targeted oncology therapies and has a late-stage pipeline aimed at unmet medical needs. For more information, visit www.sppirx.com.

Spectrum Pharmaceuticals has announced early results from Cohort 4 of the ongoing ZENITH20 clinical trial, presenting at the ESMO Congress 2021 in Paris. The study showed a 44% objective response rate (ORR) among 48 newly diagnosed patients with non-small cell lung cancer (NSCLC) exhibiting HER2 exon 20 insertion mutations. Patients received 16mg of oral poziotinib daily, with a disease control rate of 75%. Safety data revealed manageable adverse events, such as rash (35%) and stomatitis (20%). This milestone highlights the potential of poziotinib for unmet medical needs in oncology.

Spectrum Pharmaceuticals (NASDAQ: SPPI) has announced a late-breaking presentation of early efficacy and safety data for poziotinib in first-line patients with non-small cell lung cancer (NSCLC) harboring HER2 exon 20 mutations. This presentation will take place at the ESMO 2021 Congress from September 16-20. The study, part of the ZENITH20 clinical trial, aims to evaluate the efficacy and safety of poziotinib in treatment-naïve NSCLC patients. Further details include the session time, presenter, and abstract information.

Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced its financial results for the three months ending June 30, 2021, reporting a net loss of $49.9 million or $0.32 per share, up from a loss of $32.2 million in the same period last year. R&D expenses rose to $29.1 million, compared to $21.7 million in 2020. The company is focused on the NDA submission for poziotinib after positive clinical trial results, while addressing concerns regarding a CRL for ROLONTIS due to manufacturing deficiencies. Cash reserves stand at $158.8 million.